Abstract:Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulmonary edema (HAPE), a life-threatening disorder, occurring at high altitudes in non-acclimatized healthy individuals. Despite a strong physiologic rationale for using vasodilators for prevention and treatment of HAPE, no systematic studies of their efficacy have been conducted to date. Calcium-channel blockers are currently recommended for drug prophylaxis in high-risk individuals with a clear history of recurrent HAPE based on the extensive clinical experience with nifedipine in HAPE prevention in susceptible individuals. Chronic exposure to hypoxia induces pulmonary vascular remodeling and development of pulmonary hypertension, which places an increased pressure load on the right ventricle leading to right heart failure. Further, pulmonary hypertension along with excessive erythrocytosis may complicate chronic mountain sickness, another high altitude maladaptation disorder. Importantly, other causes than hypoxia may potentially underlie and/or contribute to pulmonary hypertension at high altitude, such as chronic heart and lung diseases, thrombotic or embolic diseases. Extensive clinical experience with drugs in patients with pulmonary arterial hypertension suggests their potential for treatment of high altitude pulmonary hypertension. Small studies have demonstrated their efficacy in reducing pulmonary artery pressure in high altitude residents. However, no drugs have been approved to date for the therapy of chronic high altitude pulmonary hypertension. This work provides a literature review on the role of pulmonary hypertension in the pathogenesis of acute and chronic high altitude maladaptation disorders and summarizes current knowledge regarding potential treatment options.

Effect of furosemide in the treatment of high-altitude pulmonary edema

Evaluation of renal excretion and pharmacokinetics of furosemide in rats after acute exposure to high altitude at 4300 m

Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease

Risk factors underlying high-altitude pulmonary edema in the Ecuadorian Andes

Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD

High-altitude Cerebral Edema and High-altitude Pulmonary Edema Diagnosed in the Desert: A Case Report

Clinical and Pathophysiological Features of High-altitude Pulmonary Edema in the Japanese Population: A Review of Studies on High-altitude Pulmonary Edema in Japan

Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent.

Unilateral Left-Sided High-Altitude Pulmonary Edema Following Rapid Ascent to a City in the Himalayas

Treatment of Acute Decompensated Chronic Heart Failure: Furosemide vs Furosemide and Metolazone: A Cross-Sectional Comparative Study

Effect of Continuous Furosemide Infusion on Outcome of Acute Kidney Injury.

Genetics of High-Altitude Pulmonary Edema

High-altitude retinopathy and retinal hemorrhage: A case report

Physiopathology of High-Altitude Pulmonary Edema.

Expression of Aquaporin-1 and Aquaporin-5 in a Rat Model of High-Altitude Pulmonary Edema and the Effect of Hyperbaric Oxygen Exposure

The acute effects of furosemide in acute heart failure assessed by remote dielectric sensing. A protocol

Evaluation of High Altitude Interstitial Pulmonary Edema in Healthy Participants Using Rapid 4-View Lung Ultrasound Protocol During Staged Ascent to Everest Base Camp

Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders

Lung function and blood gas of rats after different protocols of hypobaric exposure

Acute changes in cardiac dimensions, function, and longitudinal mechanics in healthy individuals with and without high‐altitude induced pulmonary hypertension at 4559 m